Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
Oncology
-
-
Verastem Oncology’s pancreatic cancer combo shows 86% OS rate
Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the…
-
EHA26: BTK combos in CLL/SLL showing earlier line promise
At the European Hematology Association (EHA) 2026 Congress, several therapies for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
-
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety data from…
-
ASCO26: GLP-1RAs linked with mortality reduction in patients with solid tumours
As glucagon-like peptide-1 receptor agonists (GLP-1RA) appear to be taking over the world, research using real-world data (RWD) is showing…
-
Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has…
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
-
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies
Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at…
-
Rezolute’s stock up on interim Phase III tumour HI data
Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s…
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
